Suggested remit: To appraise the clinical and cost effectiveness of romosozumab within its marketing authorisation for preventing osteoporotic fragility fractures in adults with severe osteoporosis at high risk of fracture.
Status In progress
Process STA 2018
ID number 3936

Provisional Schedule

Committee meeting 04 November 2021

Project Team

Project lead Shonagh D'Sylva

Email enquiries


Companies sponsors UCB Pharma (romosozumab)
  Department of Health and Social Care
  NHS East Staffordshire CCG
  NHS England
  NHS Rushcliffe CCG
  Welsh Government
Patient carer groups Action on Pain
  Arthritis and Musculoskeletal Alliance
  Back Care
  Pain Concern
  Pain Relief Foundation
  Pain UK
  Pregnancy Associated Osteoporosis (PAO) Patient Expert Group
  Royal Osteoporosis Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Women’s Health Concern
Professional groups British Geriatrics Society
  British Institute of Musculoskeletal Medicine
  British Institute of Radiology
  British Menopause Society
  British Myology Society
  British Orthopaedic Association
  British Pain Society
  British Society for Rheumatology
  British Society of Rehabilitation Medicine
  Physiotherapy Pain Association
  Primary Care Rheumatology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and the College of Radiographers
  Society of Endocrinology
  UK Clinical Pharmacy Association


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (alendronate, ibandronate, zoledronate, risedronate, raloxifene)
  Actavis UK (alendronate, ibandronate, risedronate, zoledronate)
  Amgen (denosumab)
  Atnahs (ibandronate)
  Aspire Pharma (risedronate, ibandronate, raloxifene)
  Aurobindo (alendronate, risedronate)
  Consilient Health (ibandronate)
  Creo Pharma (alendronate)
  Dr Reddy’s Laboratories (zoledronate)
  Eli Lilly (teriparatide)
  Mylan UK (alendronate, ibandronate, zoledronate)
  Novartis Pharmaceuticals (zoledronate)
  Radius Health (abaloparatide)
  Rosemont (alendronate)
  Sandoz (risedronate, ibandronate)
  Seacross Pharmaceuticals (zoledronate)
  Sun Pharmaceuticals (ibandronate, zoledronate)
  Thornton and Ross (Alendronate)
  Vygoris Limited (raloxifene)
  Zentiva (alendronate, ibandronate)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bone Research Society
  Chronic Pain Policy Coalition
  Cochrane Musculoskeletal Group
  Institute for Ageing and Health
  MRC Clinical Trials Unit
  National Institute of Health Research
  Orthopaedic Research UK
  Pain Relief Foundation


Key events during the development of the guidance:

Date Update
20 April 2021 In progress. Topic in progress
22 March 2021 - 12 April 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
20 April 0021 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance